Literature DB >> 12385013

After hMSH2 and hMLH1--what next? Analysis of three-generational, population-based, early-onset colorectal cancer families.

Mark A Jenkins1, Laura Baglietto, Gillian S Dite, Damien J Jolley, Melissa C Southey, Jonathan Whitty, Leeanne J Mead, D James B St John, Finlay A Macrae, D Timothy Bishop, Deon J Venter, Graham G Giles, John L Hopper.   

Abstract

The aim of our study was to examine the role of genetic factors on early-onset colorectal cancer after excluding the impact of germline mutations in the two major mismatch repair genes. A total of 131 incident probands, under 45 years at diagnosis of a first primary colorectal cancer selected from the Victorian Cancer Registry, and their first-and second-degree relatives, were interviewed. Germline DNA from all 12 probands with a family history meeting the modified Amsterdam Criteria for Hereditary Non-Polyposis Colorectal Cancer (HNPCC) and a random sample of 31 of the remaining probands was screened for mutations in hMSH2 and hMLH1 via manual sequencing. Germline mutations were identified in 6 of the 131 probands (5%), all from the "HNPCC" families. Of the remaining 125 probands, 51 (41%) reported at least one first-or second-degree relative with colorectal cancer with an excess of colorectal cancer in first-degree relatives (SMR = 2.7, 95% CI = 1.7-4.1, p < 0.001). The lifetime risk to age 70 for first-degree relatives was 8.0% (5.0-12.8%), compared to the Victorian population risk of 3.2% (p = 0.01). The best fitting major gene model was a recessively-inherited risk of 98% to age 70 (95% CI = 24-100%) carried by 0.17% of the population and would explain 15% of all colorectal cancer in cases with a diagnosis before age 45. Early-onset colorectal cancer is strongly familial even after excluding families found to be segregating a mutation in either of the 2 major mismatch repair genes. There is evidence for a role of yet to be identified genes associated with a high recessively-inherited risk of colorectal cancer. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12385013     DOI: 10.1002/ijc.10670

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

Review 1.  Serrated pathway colorectal cancer in the population: genetic consideration.

Authors:  Joanne Young; Mark Jenkins; Susan Parry; Bruce Young; Derek Nancarrow; Dallas English; Graham Giles; Jeremy Jass
Journal:  Gut       Date:  2007-06-12       Impact factor: 23.059

2.  Cohort Profile: The Colon Cancer Family Registry Cohort (CCFRC).

Authors:  Mark A Jenkins; Aung Ko Win; Allyson S Templeton; Maggie S Angelakos; Daniel D Buchanan; Michelle Cotterchio; Jane C Figueiredo; Stephen N Thibodeau; John A Baron; John D Potter; John L Hopper; Graham Casey; Steven Gallinger; Loic Le Marchand; Noralane M Lindor; Polly A Newcomb; Robert W Haile
Journal:  Int J Epidemiol       Date:  2018-04-01       Impact factor: 7.196

3.  Association between family history and mismatch repair in colorectal cancer.

Authors:  R P Coggins; L Cawkwell; S M Bell; G P Crockford; P Quirke; P J Finan; D T Bishop
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

4.  SISE matters: the sum of information on seventy-yr-old equivalents measures pedigree information content when assessing the risk of HNPCC in a family.

Authors:  R C Green; J R McLaughlin; H B Younghusband
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

5.  Bayesian mixture models for the incorporation of prior knowledge to inform genetic association studies.

Authors:  Brooke L Fridley; Daniel Serie; Gregory Jenkins; Kristin White; William Bamlet; John D Potter; Ellen L Goode
Journal:  Genet Epidemiol       Date:  2010-07       Impact factor: 2.135

6.  The role of SMAD4 in early-onset colorectal cancer.

Authors:  S G Royce; K Alsop; A Haydon; L Mead; L D Smith; A A Tesoriero; G G Giles; M A Jenkins; J L Hopper; M C Southey
Journal:  Colorectal Dis       Date:  2009-01-27       Impact factor: 3.788

7.  A variable age of onset segregation model for linkage analysis, with correction for ascertainment, applied to glioma.

Authors:  Xiangqing Sun; Jaime Vengoechea; Robert Elston; Yanwen Chen; Christopher I Amos; Georgina Armstrong; Jonine L Bernstein; Elizabeth Claus; Faith Davis; Richard S Houlston; Dora Il'yasova; Robert B Jenkins; Christoffer Johansen; Rose Lai; Ching C Lau; Yanhong Liu; Bridget J McCarthy; Sara H Olson; Siegal Sadetzki; Joellen Schildkraut; Sanjay Shete; Robert Yu; Nicholas A Vick; Ryan Merrell; Margaret Wrensch; Ping Yang; Beatrice Melin; Melissa L Bondy; Jill S Barnholtz-Sloan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-09-07       Impact factor: 4.254

8.  Identification of novel variants in colorectal cancer families by high-throughput exome sequencing.

Authors:  Melissa S DeRycke; Shanaka R Gunawardena; Sumit Middha; Yan W Asmann; Daniel J Schaid; Shannon K McDonnell; Shaun M Riska; Bruce W Eckloff; Julie M Cunningham; Brooke L Fridley; Daniel J Serie; William R Bamlet; Mine S Cicek; Mark A Jenkins; David J Duggan; Daniel Buchanan; Mark Clendenning; Robert W Haile; Michael O Woods; Steven N Gallinger; Graham Casey; John D Potter; Polly A Newcomb; Loïc Le Marchand; Noralane M Lindor; Stephen N Thibodeau; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-05-01       Impact factor: 4.254

9.  Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer.

Authors:  Aung Ko Win; Mark A Jenkins; James G Dowty; Antonis C Antoniou; Andrew Lee; Graham G Giles; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Dennis J Ahnen; Stephen N Thibodeau; Graham Casey; Steven Gallinger; Loïc Le Marchand; Robert W Haile; John D Potter; Yingye Zheng; Noralane M Lindor; Polly A Newcomb; John L Hopper; Robert J MacInnis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-10-31       Impact factor: 4.254

Review 10.  Risk of breast cancer in Lynch syndrome: a systematic review.

Authors:  Aung Ko Win; Noralane M Lindor; Mark A Jenkins
Journal:  Breast Cancer Res       Date:  2013-03-19       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.